Tarcocimab has a mean ocular half-life in humans of 20 days, which is 3-fold longer than faricimab Human Ocular Half-Life (Days) 10-90th percentiles 8.3 (10th percentile) 31.8 (90th percentile) 19.8 days (Mean) 5.2 (10th percentile) 11.2 (90th percentile) 7.5 days (Mean) t½ <5 days t½ >11 days Faricimab Tarcocimab Percent of Patients Each dot represents the ocular half-life from one individual patient. Blue dots are tarcocimab from the Phase 1b study of tarcocimab in patients with wet AMD, DME and RVO. Gray dots are faricimab from Genentech, Inc. PK and ER of faricimab, Report # 1105763 0% 81% 10% 10% 0 20 40 60 80 100 FARICIMAB TARCOCIMAB 25